Person:
ÇİÇEK, FURKAN CUMA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ÇİÇEK

First Name

FURKAN CUMA

Name

Filters

2020 - 20222
Reset filters

Settings

Item Type: Publication ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Radial arterial thrombosis in COVID-19: A case report
    (2022-01-01) ÇİÇEK, FURKAN CUMA; EYÜPLER, ÇAĞLA; YETGİNOĞLU, ÖZGE; AK, KORAY; KOCAKAYA, DERYA; Durmus N. S. , ÇİÇEK F. C. , EYÜPLER Ç., Omur C., YETGİNOĞLU Ö., AK K., KOCAKAYA D.
    Thrombosis due to hypercoagulable state is an important cause of morbidity and mortality in coronavirus disease 2019 (COVID-19). Increased D-dimer levels are an important marker of the presence and risk of thrombosis. In this report, we present that a 59-year-old male patient developed thrombosis in the distal radial arteries despite normal D-dimer level. The patient was treated with enoxaparin, iloprost infusion, and cilostazol. This case should lead us to be very careful that people diagnosed with COVID-19 with normal D-dimer levels may also have thrombosis.
  • No Thumbnail Available
    PublicationMetadata only
    Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib
    (SAGE PUBLICATIONS LTD, 2020) ÇİÇEK, FURKAN CUMA; Demircan, Nazim C.; Alan, Ozkan; Tuylu, Tugba Basoglu; Telli, Tugba Akin; Arikan, Rukiye; Cicek, Furkan C.; Ercelep, Ozlem; Ozturk, Mehmet A.; Cetin, Ilknur Alsan; Ergelen, Rabia; Tinay, Ilker; Babacan, Nalan Akgul; Kaya, Serap; Dane, Faysal; Yumuk, Perran F.
    Background Anti-angiogenic tyrosine kinase inhibitors, sunitinib and pazopanib, have proven efficacy in advanced renal cell carcinoma, with specific adverse events occurring during treatment process. Comorbidities can reflect functional status and have prognostic value in oncology patients. We aimed to assess the association of the Charlson Comorbidity Index with severe toxicities and mortality in renal cell carcinoma cases treated with front-line sunitinib or pazopanib. Methods Files of locally advanced and metastatic renal cell carcinoma patients who received first-line sunitinib or pazopanib were retrospectively examined. Charlson Comorbidity Index of each patient was calculated. Patients were also stratified into Memorial Sloan-Kettering Cancer Center risk groups. Predictors of dose-limiting toxicity were evaluated with binomial logistic regression analysis. Univariate and multivariate Cox regression models were utilized to determine prognostic factors for survival. Results The study included 102 patients, 64 were treated with first-line sunitinib and 38 with pazopanib. In 42 patients (41.9%), Charlson Comorbidity Index was 9 or more. Dose-limiting toxicities were significantly more frequent in Charlson Comorbidity Index >= 9 group (69% vs. 40%, p = 0.004), and Charlson Comorbidity Index independently predicted dose-limiting toxicity (Hazard ratio (HR) = 4.30, p = 0.002). After adjusting for other variables, a Charlson Comorbidity Index of >= 9 is also a significant prognostic factor for progression-free (HR = 1.76, p = 0.02) and overall survival (HR = 1.75, p = 0.03). Conclusions Charlson Comorbidity Index may be a valuable method to estimate prognosis and optimize therapy in patients with advanced renal cell carcinoma receiving first-line sunitinib or pazopanib.